Insider Purchases: Inside the Buy
Tag: insider buying
Arrow Electronics: A Straight Arrow, But the CEO Sees a Bullet
Arrow Electronics CEO Sean Kerins just bought nearly $1M of ARW stock. Is this undervalued tech distributor about to rebound, or just cruising under the radar? We take a shot at the bullseye—with puns and charts.
UPS: Shipping Value in an Expensive Market — Or Delivering a Value Trap?
UPS insiders are shipping signals of confidence 📬 with big stock purchases—even as growth slows and margins come under pressure. Should you get in on this box of value or beware what’s inside?
Progress Software CEO Buys In — Maybe It’s More Than Just... Progress?
Progress Software's CEO and a director are buying shares, signaling confidence as the company posts strong earnings and raises guidance. With institutional investors owning over 121% of the float, is this under-the-radar compounder set for a rerating?
Cogent Biosciences (COGT): The Biotech with a Plan, a Billion Cells, and a Bezuclastinib
Insiders are buying, trials are working, and Cogent just raised $230M. Meet bezuclastinib—the biotech drug with a Marvel name and real potential. 🧬💥
Will Profits From Marriott Vacations (VAC) Help You Unwind?
Insiders are buying, institutions are lounging, and dividends are flowing. Marriott Vacations Worldwide (VAC) might be your next profitable getaway — with a 3.9% yield and room to grow. But are there risks under the palm trees?
Insiders Are Buying ConocoPhillips. Should You?
Insiders are drilling into COP shares—and they're not alone. With a $10B return plan, strong reserves, and a smart buyout of Marathon Oil, ConocoPhillips might just be the contrarian pick of the year. Here's the fun, smart breakdown.
Moderna: Messenger RNA Medicines Powerhouse Sends A New Message — “Discount!”
Insiders dropped $6M on Moderna stock. With a massive mRNA pipeline and deep-pocketed backers, is this biotech beast ready to roar again?
Oscar Health: Its Own Is Shining and Insiders Knew!
Co-founder Joshua Kushner and Thrive Partners bought over $23 million of Oscar Health stock in late 2024. Since then? Record earnings, soaring revenue, and a stock still (surprisingly) within range. A healthy bet — or just a well-insured hunch?
CEO Bought Shares: Is Full House Worth Betting the House?
Full House Resorts is growing fast—but still bleeding cash. The CEO’s massive insider buy may hint at a turnaround, but with debt looming and expansion plans on the table, is FLL worth a gamble? We break it down—odds, icons, and all.
Can Robinhood Still Steal the Show?
Robinhood’s got a new backer — and it’s no amateur. Christopher Payne (ex-DoorDash, Tinder, eBay) just went all in with a bold $2M+ insider buy. Add in huge crypto growth, a string of acquisitions, and global ambitions… and suddenly Robinhood doesn’t just look ready — it looks legendary. Is $HOOD still a buy? Let’s break it down.